| Cat.No. | Name | Information |
|---|---|---|
| M6098 | Baicalein | Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM. |
| M9325 | EGTA | EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages. |
| M9330 | Brij-35 | Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability. |
| M6154 | 2-PMPA tetrasodium | 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM. |
| M2250 | Pamidronate disodium | Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis. |
| M9916 | DPPH | DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants. |
| M9194 | Insulin (human) | Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets. |
| M3409 | Formestane | Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM. |
| M9665 | N-(2-amino-2-oxoethyl)acrylamide | N-(2-Amino-2-oxoethyl)acrylamide |
| M7791 | Exo-1 | Exo1 is a reversible inhibitor of exocytosis, also a Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator. |
| M25246 | Naptumomab estafenatox | Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer. |
| M25243 | Mapatumumab | Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer. |
| M25242 | Zanolimumab | Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. |
| M25234 | Balugrastim | Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer. |
| M25233 | Tefibazumab | Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections. |
| M25231 | Adecatumumab | Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. |
| M25230 | Urtoxazumab | Urtoxazumab (TMA-15) is a humanized monoclonal antibody against Shiga toxin (Stx) 2. |
| M25228 | Pritumumab | Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research. |
| M25226 | Albinterferon alfa-2B | Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C. |
| M25223 | Aselizumab | Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma. |
| M25222 | Talizumab | Talizumab (TNX 901) is an anti-IgE humanized IgG1 monoclonal antibody. |
| M25220 | Sontuzumab | Sontuzumab (AS1402) is a humanised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer. |
| M25219 | Lumiliximab | Lumiliximab (Anti-CD23 Recombinant Antibody) is an anti-CD23 monoclonal antibody that inhibits allergen-induced responses. |
| M25218 | Galiximab | Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. |
| M25211 | Vapaliximab | Vapaliximab (2D10) is a monoclonal antibody against human VAP-1. |
| M25210 | Pascolizumab | Pascolizumab (SB-240683) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for the research of asthma. |
| M25209 | Fontolizumab | Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease. |
| M25207 | Verpasep caltespen | Verpasep caltespen (HspE7) is a recombinant fusion protein derived from Mycobacterium bovis Calmette-Guérin heat shock protein 65 (Hsp65), the C-terminal end of which is covalently linked to the E7 protein of HPV16. Verpasep caltespen can be used in the study of precancerous and cancerous lesions caused by human papillomavirus (HPV) . |
| M25200 | Efrilacedase alfa | Efrilacedase alfa is an active compound. Efrilacedase alfa can be used for various biochemical studies. |
| M25198 | Crefmirlimab | Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
